Prior view was $10.50-$10.70, consensus $10.61. Raises FY25 operational sales view to $92.7B-$93.1B from $91.6B-$92.4B, consensus $91.33B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Is Johnson & Johnson (JNJ) a Good Stock to Buy before Earnings?
- Notable companies reporting before tomorrow’s open
- Options Volatility and Implied Earnings Moves This Week, July 15 – July 18, 2025
- JNJ Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- FDA willing to trade faster drug reviews for lower prices, Bloomberg reports